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Abstract
Objective To evaluate the diagnostic accuracy and safety of extended stereotactic brain biopsy (ESBB) in a single center 
cohort with suspected primary angiitis of the central nervous system (PACNS).
Methods A standardized stereotactic biopsy targeting MRI-positive lesions and collecting samples from the meninges and 
the cortex as well as from the white matter was performed in 23 patients with clinically suspected PACNS between 2010 
and 2017. The relationship between biopsy yield and clinical characteristics, cerebrospinal fluid parameters, MR-imaging, 
time point of biopsy and exact localization of biopsy as well as number of tissue samples were examined.
Results PACNS was confirmed in 7 of 23 patients (30.4%). Alternative diagnoses were identified in 7 patients (30%). A 
shorter time period between the onset or worsening of symptoms (p = 0.018) and ESBB significantly increased the diagnostic 
yield. We observed only minor and transient postoperative complications in 3 patients (13.0%). ESBB led to a direct change 
of the therapeutic regime in 13 of 23 patients (56.5%). Careful neuropathological analysis furthermore revealed that cortical 
samples were crucial in obtaining a diagnosis.
Conclusion ESBB is a safe approach with good feasibility, even in critically ill patients, and high diagnostic accuracy in 
patients with suspected PACNS changing future therapies in 13 of 23 patients (56.5%). Early biopsy after symptom onset/
worsening is crucial and (sub)acute MRI-lesions should be targeted with a particular need for biopsy samples from the 
cortical layer.
Keywords Primary angiitis of the central nervous system · Stroke · Cerebral vasculitis · Brain biopsy · Stereotactic 
neurosurgery · Image-guided neurosurgery
Introduction
Primary angiitis of the central nervous system (PACNS) 
is a rare inflammatory disorder with an estimated annual 
incidence rate of 2–3 per one million individuals [1, 2]. 
Inflammation and consecutive destruction of medium- or 
small-sized brain vessels in the brain and spinal cord lead 
to ischemia and diverse progressive neurological defi-
cits [3]. The diagnostic workup of PACNS is challenging, 
because the clinical symptoms are heterogenous and non-
specific [4, 5]. In the absence of a tissue sample, PACNS is 
mainly a diagnosis of exclusion. Diagnosis of PACNS can 
be assumed if new neurological symptoms are present that 
cannot be explained otherwise, secondary causes of angiitis 
are excluded and cerebral angiogram and/or biopsy show 
pathological findings consistent with PACNS [4]. The likeli-
hood of correct diagnosis is increased if there are additional 
findings consistent with angiitis on ancillary testing, e.g. 
multiple ischemic or contrast enhancing lesions on MRI and 
inflammatory CSF changes. Notably, similarly pathological 
CSF exams and MRI findings also occur in other neurologic 
diseases like CNS-lymphoma or infectious CNS disease [6].
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Brain biopsy, albeit discussed controversially, remains 
the gold standard for diagnosis of PACNS. Tissue sampling 
from the meninges, the cortical surface and the deep white 
matter is considered the most accurate way to achieve a 
definite diagnosis [3, 4, 7]. Criticism of this approach stems 
from alleged high false negative rates (I) invasiveness of 
the procedure, (II) the notion that biopsies cannot be easily 
repeated multiple times in one individual, (III) and lack of 
standardized protocols (IV) [2].
Since therapy of PACNS requires long lasting and aggres-
sive immunosuppressive therapy, reliability, validity and 
safety of the diagnostic procedure are of utmost importance 
for the individual patient. A definition of how and where to 
perform a brain biopsy in patients with suspected PACNS 
has not been presented yet. Open, frame-less craniotomy 
techniques and stereotactic, frame-based approaches have 
been proposed. It furthermore remains unclear, whether 
biopsy of the cortical surface or of deep-seated white matter 
lesions is more likely to yield a positive histological result 
for PACNS or differential diagnoses.
Here, we tested a standardized stereotactic, frame-based 
biopsy technique. Samples from the three relevant anatomi-
cal compartments, i.e. meninges, cortex and white matter, 
were obtained by sequential tissue sampling along the trajec-
tory that targeted the MRI-positive lesion (extended stereo-
tactic brain biopsy; ESBB). Stereotactic tissue sampling was 
preceded by non-stereotactic superficial tissue sampling of 
the meninges and cortex directly after burr hole trepanation. 
The procedure was designed to be as minimally invasive as 
possible, making even seriously ill patients eligible for the 
procedure. We set out to assess safety and diagnostic accu-
racy of this approach in a single-center cohort of patients 
with unclear neurological symptoms and non-diagnostic 
MRI lesions. We furthermore examined patient and treat-
ment related variables in order to identify predictive factors 
for positive biopsy results.
Methods
Chart analysis
We searched the electronic medical record at the Hospital of 
the Ludwig-Maximilians University, Munich, Germany, for 
patients with suspected PACNS. 23 Patients who underwent 
extended stereotactic brain biopsy (ESBB) with cortical 
biopsy for clinically suspected or at least possible PACNS 
between 2010 and 2017 were identified and retrospectively 
analyzed. Clinical work-up of all the patients included 
MR-imaging [diffusion-weighted imaging (DWI), fluid-
attenuated inversion recovery (FLAIR), T2, susceptibility-
weighted imaging (SWI), T1 pre- and post-contrast)], MRI-
based angiography (time-of-flight and contrast enhanced 
MR-angiography), CSF-analysis (cell count and cell differ-
entiation, protein and glucose levels and oligoclonal bands) 
and laboratory tests including systemic vasculitis parameters 
such as ANA-levels and -differentiation as well as ANCA-
levels and rheumatoid factor. Furthermore, serological 
examinations and CSF-analyses for borrelia species, HIV, 
hepatitis A, B, C, VZV, HSV and TBC as well as evalu-
ation for vasculitic skin and/or ophthalmological changes 
were performed in each patient. All patients with old and 
acute ischemic brain lesions underwent cardiac examination 
including long-term electrocardiogram for 72 h and cardiac 
ultrasound examination. Conventional catheter angiography 
was performed in 12/23 patients.
Invasive brain biopsy was considered indicated when 
non-invasive testing provided inconclusive results but 
PACNS was still suspected or considered likely according to 
pertinent diagnostic criteria. We obtained data regarding (1) 
demographics; (2) CSF findings; (3) MRI findings and MR 
angiography and/or catheter angiography findings; (4) time 
point of brain biopsy in relation to symptom onset and/or 
worsening; (5) spatial relation of specimens obtained along 
the stereotactic track to MRI-positive lesions (DWI-lesions 
and/or contrast enhancing lesions) and specimen size; and 
(6) postoperative complications. Furthermore, therapy and 
1-year clinical outcome was retrospectively evaluated by 
means of the National Institutes of Health Stroke Scale 
(NIHSS) and the modified Rankin Scale (mRS). The thera-
peutic regimes of each patient after brain biopsy were taken 
from the medical reports available (n = 23). The NIHSS 
and mRS were calculated in each patient with histologi-
cally proven PACNS (n = 7) or clinically still presumable 
PACNS despite unspecific, non-diagnostic histological find-
ings (n = 5) at initial presentation and after one year follow-
up by analyzing standardized neurological examination from 
the medical reports of each patient.
Operative procedure
A frame-based multimodal imaging-guided stereotactic 
biopsy technique was used in all patients. Imaging included 
localized contrast-enhanced CT and additionally contrast-
enhanced T1 and T2-weighted MRI sequences as well as a 
contrast-enhanced MR angiography, which were automati-
cally fused with the localized CT data. For trajectory plan-
ning, a workstation was used allowing triplanar simulation 
of any trajectory. An MRI-positive lesion was always tar-
geted. A lesion was considered acute if it showed restricted 
diffusion and/or contrast enhancement. Small tissue samples 
(1  mm3) were collected in one-millimeter steps along the 
biopsy track from the brain surface towards the lesion. Addi-
tionally, multiple samples were collected with a biopsy for-
ceps directly from the cortical surface in the direct vicinity 
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of the trajectory. ESBB was conducted using a 1 cm burr 
hole.
Neuropathological analysis
Stereotactic biopsy samples of a maximum size of 1  mm3 
were fixed with 4% neutral buffered formalin (Microcos 
GmbH, Garching, Germany), paraffin-embedded and rou-
tinely stained for Hematoxylin and Eosin (H&E), Elastica 
van Gieson (EvG), Periodic acid-Schiff stain (PAS) and 
Gomori (Gom). Subtypes of leucocytes were differentiated 
by immunohistochemical staining against surface antigens 
CD3 (polyclonal, 1:50, Agilent Technologies, Santa Clara, 
CA, USA), CD20 (L26, 1:100, Agilent Technologies), CD45 
(2B11 + PD7/26, 1:400, Bio SB, Santa Barbara, CA, USA) 
and CD68 (KP1, 1:100, Agilent Technologies). In case 
of suspected cerebral amyloid angiopathy (CAA), Congo 
red stain and immunohistochemical staining against beta-
Amyloid (4G8, 1:5000, Covance, Princeton, NJ, USA) were 
performed in addition.
Stained slides of tissue samples from 23 cases were sys-
tematically reviewed for the morphological criteria of vas-
culitis: Trans/intramural inflammatory infiltrate and destruc-
tion of the vascular wall of intraparenchymal vessels. As 
PACNS typically affects small vessels with a diameter of 
less than 100 µm, the full picture of vascular pathology is 
usually well depicted within a biopsy sample, if present. 
Thus, the small biopsy specimens of stereotactic biopsies 
ought to be sufficient to make a histological diagnosis of 
CNS vasculitis, accurate sampling provided.
Statistics
For quantitative comparisons between groups the Chi square 
test was used for nominal variables and the Mann–Whitney 
U test was applied for ordinal variables. p values below 0.05 
were considered significant.
Ethics
The study was approved by the local ethics commission 
of the Ludwig-Maximilians University (Nr. 17-174) and 
was performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsiniki and ist later 
ammendments.
Results
Between 2010 and 2017, 23 patients (11 females, 48%) 
received ESBB for clinically suspected or at least possi-
ble PACNS according to current guidelines and after thor-
ough clinical work-up without a definitive diagnosis. A 
stereotactic brain biopsy of an ischemic or contrast enhanc-
ing lesion was conducted in each patient (n = 23; 100%), 
an additional cortical surface and meningeal biopsy in 19 
patients (83%). In 10 patients (43%) an acute lesion (either 
DWI-positive or contrast enhancing) was the exact biopsy 
localization, in 13 patients (57%) older, already DWI-nega-
tive, FLAIR-positive ischemic lesions.
In 7/23 patients (30%) a definite diagnosis of PACNS 
was made histologically. Thereof, ß-amyloid related angiitis 
(ABRA) was found in 2, lymphocytic vasculitis in 4 and 
granulomatous vasculitis in 1. A different and definite diag-
nosis could be made in 7/23 patients (30%). These diag-
noses included cerebral amyloid angiopathy with/without 
inflammation (CAA; n = 3), encephalitis, intravascular 
diffuse large B cell lymphoma of the CNS, a demyelinat-
ing lesion and encephalitis (n = 1 each). No definite histo-
pathological diagnosis could be made in 9/23 cases (39%). 
In one of these cases, even though a definite histopatho-
logical diagnosis of PACNS could not be made, the his-
topathological results were suspect of PACNS. Although 
the biopsy was non-diagnostic with unspecific results (i.e. 
gliosis with unspecific inflammatory changes), in 5 of these 
9 cases (21.7%), PACNS was still very likely and immuno-
suppressive treatment was initiated. In the remaining 4 cases 
the clinical course and additional tests (i.e. extended and 
repeated laboratory tests, repeated brain-MRI, skin biopsy) 
made other diagnoses than PACNS more likely, which was 
posterior reversible encephalopathy syndrome (PRES), Ehr-
mann Sneddon´s syndrome, primary antiphospholipid syn-
drome (APS) and unclassified systemic vasculitis with CNS-
involvement. These cases represent true-negative cases.
Clinical (i.e. headache, focal neurological deficits etc.) 
characteristics, CSF findings, MRI findings and conventional 
angiography could not reliably differentiate between patients 
with biopsy proven PACNS and patients with a definite 
alternative diagnosis or unspecific histological changes in 
brain biopsy (Table 1). Headache seemed to be more present 
in patients with confirmed PACNS (57%) as compared to the 
control group without vasculitis (19%) (p = 0.066). Only one 
patient received immunosuppressive therapy with high-dose 
methylprednisolone before ESBB.
In 6 cases a definite diagnosis could be made both from 
samples taken along the stereotactic track and from sam-
ples taken by cortical/meningeal biopsy (44% of positive 
cases). In 6 cases, only samples obtained stereotactically 
revealed the diagnosis (43%), but only in 2 cases (14%) the 
diagnosis was made based on samples obtained by direct 
cortical/meningeal biopsy only. Thus, despite lacking statis-
tical significance, there was a trend towards better diagnostic 
accuracy in samples obtained stereotactically (p = 0.084). 
Considering only PACNS cases, we found that PACNS was 
diagnosed based on samples taken along the stereotactic 
track in 5 cases (71% of PACNS cases). Samples taken both 
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along the stereotactic track and by direct cortical/menin-
geal biopsy formed the basis for the diagnosis in 1 PACNS 
case. PACNS was diagnosed based only on cortical/menin-
geal samples in 1 case. However, careful neuropathological 
review of the samples revealed that samples from the corti-
cal layer, rather than from the white matter, either obtained 
stereotactically or by direct cortical biopsy, were crucial in 
all cases for making the diagnosis.
Differential diagnoses were made based on samples 
obtained stereotactically in 1 case, on samples obtained both 
stereotactically and by direct cortical biopsy in 5 cases and 
by cortical biopsy only in 1 case.
Biopsy of acute lesions (either DWI-positive or contrast 
enhancing) did not show a higher accuracy as compared to 
older, post-ischemic lesions (p = 0.28). However, the time 
point of biopsy was critical, since diagnostic accuracy signif-
icantly improved, when the tissue samples were taken within 
the first 5 days after symptom onset or worsening (p = 0.018) 
(Table 2). The sample size was comparable in all cases (1 
 mm3) due to a standardized operative approach in all cases 
with use of a 1 mm biopsy forceps. The mean number of 
tissue samples obtained from the stereotactic trajectory was 
15 (range 3–21) and the mean number of samples taken from 
the cortical surface was 10 (range 0–24). The number of 
samples did not differ significantly between patients with 
and without histologically confirmed PACNS.
Direct comparison of the patients with biopsy-proven 
PACNS (n = 7) with the subgroup with still suspected 
PACNS despite non-diagnostic brain biopsy showing only 
unspecific gliosis and inflammation (n = 5) revealed the 
following differences: The mean age in the biopsy-proven 
PACNS patients was significantly higher (p = 0.015), the 
CSF-protein levels were higher in this subgroup (p = 0.015) 
and the rate of patients with headache (p = 0.038) and 
Table 1  Whole study group (n = 23): Demographics, clinical characteristics, CSF, MRI and conventional angiography results & biopsy variables
MRI magnetic resonance imaging, CSF cerebrospinal fluid, WBC white blood cells, OCBs oligoclonal bands, WML white matter lesions
All patients (n = 23) Biopsy positive for 
PACNS (n = 7)
Biopsy negative for 
PACNS (n = 16)
P value
Age (Mean ± SD) 57.5 ± 16.5 67 ± 10 53.0 ± 17.0 0.051
Sex 0.752
 Male (%) 12 (52.2%) 4 (57.1%) 8 (50%)
 Female (%) 11 (47.8%) 3 (42.9%) 8 (50%)
Clinical characteristics
 Headache (%) 7 (30.4%) 4 (57.1%) 3 (18.8%) 0.066
 Focal deficits (%) 20 (87.0%) 7 (100%) 13 (81.3%) 0.22
 Cognitive/behavioral changes (%) 12 (52.2%) 3 (42.9%) 9 (56.3%) 0.55
 Epilepsy 3 (13.0%) 2 (28.6%) 2 (12.5%) 0.54
 Decreased vigilance state (GCS < 15) (%) 2 (8.7%) (GCS 13 each) 0 (0%) 2 (12.5%) 0.33
CSF results
 WBC (cells/mm3) (Median) 2 (0–56) 2 (1–56) 2 (0–25) 0.14
 Protein (mg/dl) (Median) 50 (30–266) 62 (39–266) 45 (31–250) 0.11
 Glucose (mg/dl) (Median) 65 (54–84) 65 (54–81) 63 (58–84) 0.75
 OCBs % 6 (26%) 3 (43%) 3 (19%) 0.31
MRI findings
 Acute ischemic infarction (%) 16 (69.6%) 5 (71.4%) 10 (62.5%) 0.90
 Old ischemic infarction (%) 15 (65.2%) 5 (71.4%) 10 (62.5%) 0.68
 WML (%) 15 (65.2%) 5 (71.4%) 10 (62.5%) 0.33
 Macrobleeds (%) 2 (8.7%) 0 (0%) 2 (12.5%) 0.14
 Microbleeds (%) 8 (34.8%) 4 (57.1%) 4 (25%) 0.35
 Sulcal siderosis/SAH (%) 4 (17.4%) 2 (28.6%) 2 (12.5%) 0.39
 Contrast enhancing lesions (%) 9 (39.1%) 5 (71.4%) 4 (25%) 0.10
Brain biopsy variables
 Number of specimens (cortical surface) (Median) 10 (0–24) 8 (0–23) 10 (0–24) 0.27
 Number of specimens (stereotactic trajectory) (Median) 11 (3–21) 13 (7–21) 10 (3–21) 0.19
 Time point of biopsy (days after symptom onset/worsen-
ing; median)
5 (2–90) 4 (2–5) 22 (2–90) 0.018*
 Exact biopsy localisation (acute lesion) (%) 10 (43.5%) 6 (85.7%) 4 (25%) 0.28
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microbleeds (p = 0.038) was also higher in this subgroup 
(see Table  2). The biopsy time point was significantly 
delayed in the subgroup with suspected PACNS, but only 
unspecific and thus non-diagnostic brain biopsy results 
(p = 0.004). Correspondingly, less often acute lesions (i.e. 
either DWI-positive or contrast-enhancing lesions) were 
the target of brain biopsy in this subgroup (p = 0.034) (see 
Table 2).
Adverse events
Wound infection requiring operative revision occurred in 1 
patient. Another patient suffered from postoperative delir-
ium. In one case, asymptomatic minor bleeding occurred at 
the biopsy site which did not require intervention. No fur-
ther postoperative complications occurred. In total, transient 
morbidity occurred in 13.0% of cases. No permanent mor-
bidity or procedure-related mortality was observed.
Therapy and clinical course
Altogether, the results obtained from the brain biopsy 
directly changed the therapeutic regime in 13 of the 23 
patients (56.5%), which were the 7 patients with confirmed 
PACNS and 6 of the 7 patients with a definite diagnosis 
other than PACNS (CAA-ri n = 2; intravascular lymphoma 
n = 1; GvHD-encephalitis n = 1; tumefactive multiple sclero-
sis n = 1; neurotuberculosis with secondary vasculitis n = 1). 
In addition, in another 2 cases with only unspecific histo-
pathological findings (i.e. gliosis and unspecific inflamma-
tory changes) the brain biopsy results guided further diag-
nostics thus leading to other diagnoses than PACNS such as 
Table 2  Subgroup analysis (histologically confirmed vs. suspected biopsy-negative PACNS): demographics, clinical characteristics, CSF, MRI 
and conventional angiography results & biopsy variables
MRI magnetic resonance imaging, CSF cerebrospinal fluid, WBC white blood cells, OCBs oligoclonal bands, GCS Glasgow Coma Scale, SAH 
subarachnoid hemorrhage, WML white matter lesions
All PACNS 
patients (n = 12)
Histologically con-
firmed PACNS (n = 7)
Suspected, biopsy-nega-
tive PACNS (n = 5)
P value
Age (Mean ± SD) 59.1 ± 12.9 67 ± 10.4 48 ± 5.6 0.015*
Sex 0.80
 Male (%) 6 (50%) 3 (42.9%) 2 (40%)
 Female (%) 6 (50%) 4 (57.1%) 3 (60%)
Clinical characteristics
 Headache (%) 4 (33.3%) 4 (57.1%) 0 (0%) 0.038*
 Focal deficits (%) 12 (100%) 7 (100%) 5 (100%) 1
 Cognitive/behavioral changes (%) 4 (33.3%) 3 (42.9%) 1 (20%) 0.41
 Epilepsy 2 (16.7%) 2 (16.7%) 0 (0%) 0.19
 Decreased vigilance state (GCS < 15) (%) 0 (0%) 0 (0%) 0 (0%) 1
CSF results
 WBC (cells/mm3) (Median) 1.5 (0–56) 2 (1–56) 1 (0–4) 0.51
 Protein (mg/dl) (Median) 49.5 (31–266) 62 (39–266) 35 (30–56) 0.015*
 Glucose (mg/dl) (Median) 65.5 (54–81) 65 (54–81) 66 (59–70) 0.57
 OCBs % 6 (50%) 3 (42.9%) 3 (60%) 0.12
MRI findings
 Acute ischemic infarction (%) 10 (83.3%) 5 (71.4%) 5 (100%) 0.19
 Old ischemic infarction (%) 10 (83.3%) 5 (71.4%) 5 (100%) 0.19
 WML (%) 7 (58.3%) 5 (71.4%) 2 (40%) 0.52
 Macrobleeds (%) 0 (0%) 0 (0%) 0 (0%) 0
 Microbleeds (%) 3 (25%) 4 (57.1%) 0 (0%) 0.038*
 Sulcal siderosis/SAH (%) 2 (16.7%) 2 (28.6%) 0 (0%) 0.19
 Contrast enhancing lesions (%) 3 (35%) 3 (42.9%) 0 (0%) 0.09
Brain biopsy variables
 Number of specimens (cortical surface) (Median) 9 (0–23) 8 (0–23) 14 (8–16) 0.46
 Number of specimens (stereotactic trajectory) (Median) 15.5 (7–21) 13 (7–21) 21 (9–21) 0.14
 Time point of biopsy (days after symptom onset/worsen-
ing; median)
5 (2–45) 4 (2–5) 30 (22–45) 0.004**
 Exact biopsy localisation (acute lesion) (%) 6 (50%) 6 (83.3%) 0 (100%) 0.0034**
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Ehrmann–Sneddon´s syndrome and primary antiphospho-
lipid antibody syndrome. In 5/9 patients PACNS remained 
the most likely differential diagnosis despite only unspecific 
gliosis and inflammatory findings obtained by brain biopsy. 
Due to recurrent ischemic events in these patients with con-
comitant morbidity immunosuppression with either high-
dose steroids alone (i.e. methylprednisolone 5 × 1000 mg) 
followed by oral tapering of steroids (n = 3), high-dose ster-
oids plus cyclophosphamide (n = 1) or high-dose steroids 
plus azathioprine (n = 1) was started (see Table 3). The 7 
patients with definite PACNS, as confirmed by ESBB, were 
treated either with high-dose steroids plus cyclophospha-
mide (n = 5) or high-dose steroids in combination with aza-
thioprine (n = 2) (see Table 3).
The overall outcome was favorable in the 7 patients with 
histologically confirmed PACNS as well as the remaining 
5 cases with presumable PACNS but without diagnostic 
biopsy results (see Table 4). One patient with confirmed 
PACNS died within one year due to suicide as a direct con-
sequence of organic affective disorder despite psychiatric 
treatment. All other patients stabilized under immunosup-
pression and improved clinically as measured by NIHSS as 
well as in terms of their functional independence in everyday 
life as measured by mRS (see Table 4). No severe adverse 
events of immunosuppression were observed.
Discussion
PACNS comprises a heterogenous group of rare, inflam-
matory vessel disorders affecting the brain and spinal cord. 
Brain biopsy is considered the diagnostic gold standard, but 
there is no consensus on timepoint, surgical method and ana-
tomical location of tissue sampling. Some authors question 
the indication of brain tissue sampling due to alleged low 
diagnostic yield and surgery-associated complication rates. 
Addressing these uncertainties, we investigated systematic 
stereotactic brain biopsies of different compartments in 
angiography-negative patients with MRI lesions and clini-
cal findings consistent with PACNS. Lesions were targeted 
Table 3  Overview of the 23 cases with biopsy results, final clinical diagnoses and immunosuppression/specific therapies
ABRA amyloid ß-related angiitis, APS antiphospholipid antibody syndrome, Aza azathioprine, CAA cerebral amyloid angiopathy, CAA-ri cer-
ebral amyloid angiopathy-related inflammation, Cyc cyclophosphamide, GvHD graft versus host disease, MS multiple sclerosis, PACNS primary 
angiitis of the central nervous system, PRES posterior reversible encephalopathy syndrome
Patient (Nr.) Diagnosis brain biopsy Final diagnosis Immunosuppression/specific therapy
1 ß-amyloid-related small vessel vasculitis ABRA Cyc. plus high-dose steroids
2 lymphocytic small vessel vasculitis PACNS Cyc. plus high-dose steroids
3 granulomatous small vessel vasculitis PACNS Cyc. plus high-dose steroids
4 ß-amyloid-related small vessel vasculitis ABRA Cyc. plus high-dose steroids
5 lymphocytic small vessel vasculitis PACNS Cyc. plus high-dose steroids
6 lymphocytic small vessel vasculitis PACNS Aza. plus high-dose steroids
7 Lymphocytic small vessel vasculitis PACNS Aza. plus steroids
8 Cerebral amyloid angiopathy with perivascular 
inflammation
CAA-ri High-dose steroids
9 ß-amyloid angiopathy CAA None
10 Intravascular diffuse large B-cell lymphoma Intrasvascular lymphoma Chemotherapy (R-CHOP)
11 Encephalitis with T-cell and macrophage 
infiltrates
GvHD-encephalitis Intravenous immunglobulines
12 Cerebral amyloid angiopathy with perivascular 
inflammation
CAA-ri High-dose steroids
13 Tuberculous granulomas and vasculitis Neurotuberculosis and vasculitis Antibiotics plus oral steroids
14 Demyelinating CNS-inflammation MS, tumefactive High-dose steroids
15 Unspecific gliosis PRES None
16 Unspecific gliosis Systemic vasculitis with CNS-involvement Cyc. plus high-dose steroids
17 Unspecific gliosis Ehrmann-Sneddon´s syndrome None
18 Unspecific gliosis APS None
19 Unspecific gliosis PACNS, presumable High-dose steroids
20 Unspecific gliosis PACNS, presumable High-dose steroids
21 Unspecific gliosis PACNS, presumable High-dose steroids
22 Unspecific gliosis PACNS, presumable Aza. plus high-dose steroids
23 Unspecific gliosis PACNS, presumable Cyc. plus high-dose steroids
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utilizing a frame-based stereotactic approach and biopsies 
were taken consecutively beginning with the meninges, 
continuing with the cortex and finally acquiring specimens 
along the trajectory targeting the deeper-seated, MRI-pos-
itive lesions. Patient-related data and clinical parameters 
were analyzed and correlated with the diagnostic yield of 
the procedure.
Out of 23 patients (100%) meeting the criteria men-
tioned above, brain tissue sampling led to definite diagnosis 
of PACNS or differential diagnoses in 14 (61%) patients. 
Definite diagnosis of PACNS was determined histologi-
cally in 7 (30%). Although biopsy showed only unspecific 
inflammatory changes and gliosis without a definite diag-
nosis of PACNS in another 5 (22%) individuals, PACNS 
was suspected due to the clinical course with recurrent 
ischemic strokes and after thorough and repeated exclusion 
of alternative diagnoses. Investigation of these two groups 
showed that the timeframe between symptom onset or wors-
ening and stereotactic biopsy in patients with histological 
diagnosis of PACNS was significantly shorter than in the 
subgroup that was diagnosed based on clinical symptoms 
and imaging features (p = 0.018). This also held true for 
patients receiving alternative histological diagnoses, sug-
gesting that early tissue sampling after clinical presentation 
is pivotal. Furthermore, acute, i.e. diffusion-positive or con-
trast-enhancing, lesions were targeted in 83% of later his-
tologically confirmed PACNS cases. On the contrary, all 5 
clinically diagnosed patients that had negative biopsy results 
displayed MRI-patterns of chronic or subacute lesions, 
underwent stereotactic biopsy significantly later after clini-
cal deterioration, presented with lower total CSF-protein and 
less headache. Altogether, this suggests a dormant phase of 
the disease at the time of stereotactic brain biopsy which 
might have led to negative biopsy results.
Our biopsy technique involved stereotactic tissue sam-
pling but also non-stereotactic superficial tissue sampling 
from the meninges and cortex that was conducted directly 
after burr hole trepanation. Comparison of the respective 
diagnostic accuracy showed that diagnosis could be made 
based on either approach in 44% of positive cases. In 43% 
of patients, only specimens obtained stereotactically led to 
a diagnosis. Open and non-stereotactic cortical layer biopsy 
alone was crucial for diagnosis in 14%. Thus, despite lack-
ing statistical significance, there was a trend towards bet-
ter diagnostic accuracy in samples obtained stereotactically 
(p = 0.084). In 7 (30%) out of 23 patients, PACNS was 
confirmed histologically. Differential diagnoses could be 
confirmed in additional 7 patients and comprised cerebral 
Table 4  Outcome measures 
in all the 12 patients with 
immunosuppressive treatment 
due to either histologically 
confirmed or clinically 
suspected PACNS
NIHSS National Institute of Health Stroke Scale, mRS modified Rankin Scale




1 ABRA (biopsy-based) Cyc. plus high-dose steroids NIHSS 4/0
mRS 2/0
2 PACNS (biopsy-based) Cyc. plus high-dose steroids NIHSS 8/death
mRS 3/death
3 PACNS (biopsy-based) Cyc. plus high-dose steroids NIHSS 7/2
mRS 3/1
4 ABRA (biopsy-based) Cyc. plus high-dose steroids NIHSS 7/3
mRS 3/2
5 PACNS (biopsy-based) Cyc. plus high-dose steroids NIHSS 5/1
mRS 3/1
6 PACNS (biopsy-based) Aza. plus high-dose steroids NIHSS 7/3
mRS 3/1
7 PACNS (biopsy-based) Aza. plus steroids NIHSS 6/3
mRS 3/1
8 PACNS, presumable High-dose steroids NIHSS 7/2
mRS 3/1
9 PACNS, presumable High-dose steroids NIHSS 10/6
mRS 3/2
10 PACNS, presumable High-dose steroids NIHSS 9/6
mRS 3/2
11 PACNS, presumable Aza. plus high-dose steroids NIHSS 6/3
mRS 2/1
12 PACNS, presumable Cyc. plus high-dose steroids NIHSS 7/3
mRS 3/1
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amyloid angiopathy with/without inflammation (CAA; 
n = 3), infectious encephalitis with vasculitis, intravascular 
diffuse large B cell lymphoma of the CNS, a demyelinating 
lesion and GvHD-encephalitis (n = 1 each).
We analyzed histologically confirmed PACNS cases and 
compared diagnostic yield of white matter specimens ver-
sus cortical specimens, irrespective of whether obtained 
stereotactically of non-stereotactically. Thorough neuro-
pathological investigation of the tissue with confirmed 
PACNS showed, that the typical histopathological pattern 
of PACNS was more prevalent in the cortical layer and 
essential for diagnosis in all PACNS cases. In most cases, 
stereotactic brain biopsy provided pivotal cortical tissue (6 
out of 7 patients, 86%). In one case, direct non-stereotactic 
tissue sampling of the cortex alone let to definite diagnosis. 
Despite this lower yield, we still propose including direct, 
non-stereotactic biopsies in addition to the stereotactic 
approach, since stereotactic tissue sampling does not neces-
sarily guarantee obtaining cortical layer specimens.
We report a complication rate of 13% in our cohort with 
only transient morbidity and no major complication. Stereo-
tactic biopsy led to a therapy change in 57% of cases and 
prevented initiation of immunosuppressive treatment in 9%. 
In conclusion, there were only minor complications associated 
with this minimally invasive surgical procedure and histologi-
cal analyses had great impact on further treatment regimens.
Successfully diagnosing PACNS surgically remains chal-
lenging. Results vary widely, with diagnostic yields being 
in line with our findings or considerably lower. In a recently 
published case series of patients with unclear neurological 
decline who underwent brain biopsies, PACNS was only 
confirmed histologically in 2 out of 16 patients with clini-
cally suspected PACNS [8]. A recent case series including 
79 patients with suspected PACNS who underwent brain 
biopsy showed histopathological confirmation of PACNS 
in only 11% of cases with alternative diagnoses in 30% [9]. 
This very low diagnostic yield for brain biopsies in sus-
pected PACNS was contradicted by a meta-analysis of stud-
ies which dealt with brain biopsies for unclear neurological 
syndromes [10]. Here, the authors found an overall diagnos-
tic success rate of 75% in patients with suspected PACNS 
with a histological diagnosis of PACNS in 34% of patients. 
This was based on 3 studies with a total of 106 patients 
[11–13]. This is in line with our finding of a total diagnostic 
yield of 60% and a histopathological confirmation rate for 
PACNS of 30%. The wide range of diagnostic success rates 
in these studies might be attributed to inconsistent diagnos-
tic and heterogeneous operative approaches. Additionally, 
PACNS comprises different subgroups of inflammatory ves-
sel diseases and can be stratified according to angiography-
negativity with respective biopsy-positivity and vice versa 
[14]. The former group represents a PACNS type most likely 
predominantly affecting small vessels that usually cannot 
be visualized on conventional angiogram [14]. Due to this 
multifactorial heterogeneity, it is in our view important that 
biopsies in patients with possible or suspected PACNS are 
conducted in a standardized and consistent manner across 
all cases.
In addition to false-negative cases of PACNS due to miss-
ing or insufficient brain biopsy, we also have to discuss the 
important issue of false-positive PACNS-diagnoses. To suc-
cessfully avoid false-positive diagnoses of PACNS, a clearly 
defined, standardized and stepwise diagnostic algorithm in 
all such cases with possible PACNS is mandatory [15–17]. 
The list of diseases or conditions mimicking PACNS, either 
when medium-sized vessels or small-vessels are affected, 
is extensive and most of such alternative diagnoses can be 
successfully made without brain biopsy/histology [14, 17]. 
This is of particular clinical relevance, since dispensable 
immunosuppressive treatments with its multiple side effects 
and potentially serious complications due to a false-positive 
diagnosis of PACNS should be avoided [16]. Even techno-
logical advances in imaging techniques in the last decade 
such as black blood based vessel wall MRI of intracranial 
arteries allows no clear differentiation between distinct con-
ditions such as advanced atherosclerosis, reversible cerebral 
vasoconstriction syndrome (RCVS), Moya-Moya-angiopa-
thy (MMA) and PACNS, all of them leading to stenosis or 
occlusion of medium-sized intracranial arteries [14, 18]. 
Single center cohort studies of PACNS patients are limited 
by relatively small sample sizes. The broad clinical spec-
trum of PACNS and all its differential diagnoses cannot 
be easily mirrored adequately in small patient cohorts and 
comparisons between different studies are inevitably biased. 
However, these limitations could only be overcome by either 
large, multicenter prospective trials or large retrospective 
register studies. A selection bias in the clinical decision for 
or against brain biopsy might impact the clinical characteris-
tics and histopathological findings. The good safety data on 
extended stereotactic brain biopsies in our cohort also might 
be influenced by the selection of the patients for biopsy, 
which means caution is required when comparing our safety 
data with data from other PACNS-studies. A relevant limita-
tion of our study definitely is the quite low rate of conven-
tional angiography of the cerebral arteries (52.2%) before 
brain biopsy, since some differential diagnoses of PACNS 
such as Divry van Bogaert syndrome or RCVS can only be 
diagnosed by conventional angiography [19, 20]. Particu-
larly for the differentiation of RCVS from PACNS conven-
tional angiography with intraarterial nimodipin application 
is extremely helpful [20]. However, conventional angiogra-
phy probably would not have been of additional diagnostic 
value in most of our cases, since most patients presented 
with small vessel disease. Different forms of PACNS seem 
to exist with either at least predominant or even isolated 
affection of small vessels or vice versa predominant or even 
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isolated affection of medium-sized vessels, as can be seen in 
the quite low rates of pathological findings in conventional 
angiography (0–33%) in the former scenario and comparable 
low rates of pathological findings in brain biopsy in the latter 
form (0–25%) [1, 6, 13, 14, 21].
In retrospect, one may criticize, that some of the alter-
native diagnoses in our patients such as PRES, APS, Ehr-
mann–Sneddon’s syndrome, tumefactive MS and neurotu-
berculosis with secondary vasculitis could have been made 
without brain biopsy, when following a clearly defined and 
stepwise diagnostic algorithm [15, 17]. However, cases 
sometimes present quite atypical or disease-defining bio-
markers or specific laboratory tests might be ambiguous or 
false-negative initially or even during a longer course, so 
that there is a need for brain biopsy at the end. Nevertheless, 
we want to point out, that before obtaining brain biopsy in 
possible or suspected PACNS a clearly defined and stepwise 
diagnostic algorithm with extensive investigations always 
should be applied [15, 16].
We conclude that stereotactic brain biopsy in patients 
with suspected PACNS should not be delayed, when all the 
non-invasive diagnostic tests before—following a strict and 
extensive algorithm—do not lead to a definite diagnosis. Ste-
reotactic biopsy should include meningeal, superficial corti-
cal as well as intralesional specimens. Aiming at acute MRI 
lesions might improve diagnostic yield for positive diagno-
ses in general. It is a safe and minimally invasive procedure 
that directly impacts clinical decision making and leads to a 
definite diagnosis in 61% of patients.
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